Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug

Jubilant Pharmova arm receives ANDA approval for psychoneurosis drug

By: IPP Bureau

Last updated : March 19, 2022 5:56 pm



The generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis


Jubilant Pharmova has announced that Jubilant Pharma, a material wholly-owned subsidiary of the company, through one of its subsidiaries, Jubilant Cadista Pharmaceuticals has received Abbreviated New Drug Application (ANDA) final approval for Doxepin Hydrochloride Capsules, 10 mg, 25mg, 50mg, 75mg, and 100mg, the generic version of Sinequan, which is used for the treatment of anxiety, depression, and other target symptoms of psychoneurosis.

Jubilant Pharmova Jubilant Pharma ANDA Sinequan

First Published : March 19, 2022 12:00 am